Abbvie Inc at Cowen HealthCare Conference Transcript

Mar 04, 2020 / 04:20PM GMT
Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Representing the company is Mike Severino, Vice Chairman and President; and Rob Michael, who is Executive Vice President and Chief Financial Officer.

Before we get into Q&A, I'd just like to say that when Cowen looks at AbbVie, we see a company that is delivering on its new product portfolio that is prepared for the HUMIRA patent expiration that has executed brilliantly since its public inception 6, 7 years ago, never having missed an earnings number, offers a 5.5% dividend yield, and sells at 8x 2020 numbers. That seems like a buy to us. That seems like a must-own stock.

Questions and Answers:

Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

So Mike, with that, the topic, of course, on everyone's mind right now is the Allergan transaction, and the company is saying you'll close in Q1. I mean Q1 is only a few more days to go. So can you talk about the latest relative to the transaction and
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot